This suggests that the combination anti‐PGAP3 and anti‐ERBB2 agents may augment the efficacy of ERBB2‐targeted therapy, making it a better treatment strategy for stage III/IV GC.33 This evidence concerns the gene PGAP3 and gastric cancer.